Adding to Agent's post also remember Wall St stock analysts advised only 2 days ago that Dendreon is heavily undervalued with a further +37% upside.
Agent, I believe the exact quote from medicare was US$93,000 per Provenge treatment - although with inflation your 100k mark might be closer by the time CVac becomes commercialized.
Quick note to those expecting a re-trace: I believe the PRR charts might prove futile given the fact that many are anticipating the imminent news of both Nasdaq listing and/or design details of the breast cancer phase 2/3 trial program
the next must-buy biotech is anyone's guess, page-15
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.0¢ |
Change
-0.005(1.41%) |
Mkt cap ! $508.4M | |||
| Open | High | Low | Value | Volume |
| 35.5¢ | 37.0¢ | 35.0¢ | $906.4K | 2.522M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 71513 | 35.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.0¢ | 113290 | 6 |
View Market Depth
| Last trade - 16.10pm 20/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |